The beneficial effect on ventricular arrhythmias may be attributed to a direct pharmacological effect of sacubitril/valsartan on cardiac reverse remodeling and/or small-conductance Ca2+-activated potassium channel type 2 (KCNN2)-associated electrical remodeling (27, 28). The gene discussed is KCNN2; the disease is Ventricular arrhythmia.